Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**HELLO-B** is an oral fixed-dose vitamin B complex dietary supplement marketed in Thailand for neurological conditions associated with disturbances in metabolic functions influenced by B-complex vitamins. Each tablet contains thiamine mononitrate 100 mg, pyridoxine hydrochloride 200 mg, and cyanocobalamin 200 mcg. The product is used for conditions including diabetic and alcoholic polyneuropathy, peripheral neuritis, post-influenzal neuropathy, neuritis and neuralgia of the spinal nerves, facial paresis, cervical syndrome, low back pain, and ischialgia. Its pharmacologic activity is nutritional replacement of vitamins B1, B6, and B12, which act as metabolic cofactors important for neuronal energy metabolism, neurotransmitter-related pathways, and nervous-system function. HELLO-B is manufactured by Umeda and marketed by Charoon Bhesaj.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HELLO-B.